• Gain a better understanding of biologic agents, risk factors and potential MOA's as it relates to safety • Discuss complexities in clinical evaluation of and reporting of safety considerations in the era of biologics 
Immunogenicity
• Immunogenicity = immune response to a therapeutic protein (biologic) -Wanted immunogenicity: The injection of an antigen (e.g., vaccine) leads to an immune response against the pathogen. -Unwanted immunogenicity: The organism mounts an immune response against an antigen which is undesired.
• Immunogenicity is generally not a concern for small molecules, but is a significant concern for biologics • Clinical consequences of unwanted immunogenicity can range from redness at site of injection to rash to anaphylaxis and even death. -It is imperative that the phase 2 and 3 study design have a sample collection and storage plan that will be used for assessment.
-Assays that will be utilized in these phases include sensitive and drug tolerant ADA screens and potentially (if a positive ADA) a sensitive and drug tolerant neutralizing ADA screen (that is usually cell based).
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What are regulators looking for?
• They want to understand the clinical consequences -safety and efficacy • They want to be able to predict who is at risk • They want to understand the mechanism by which the immune system is activated 24 Immunogenicity • Perform additional experimental work to understand the impact of soluble CD30 in serum samples on the determination of anti-drug antibodies Yervoy (ipilimumab) • To develop a validated, sensitive, and accurate assay for the detection of binding antibodies to ipilimumab, including procedures for accurate detection of antibodies to ipilimumab in the presence of ipilimumab levels that are expected to be present in the serum or plasma at the time of patient sampling. • To develop a validated, sensitive, and accurate assay for the detection of neutralizing antibodies to ipilimumab, including procedures for accurate detection of neutralizing antibodies to ipilimumab in the presence of ipilimumab levels that are expected to be present in the serum or plasma at the time of patient sampling. In the event such an assay can not be developed, evidence of due diligence in attempting to develop the assay will be provided. • To conduct an assessment of anti-drug antibody (ADA) response and neutralizing ADA responses to ipilimumab with a validated assay (required in PMR 2 and 3) capable of sensitively detecting ADA responses in the presence of ipilimumab levels that are expected to be present at the time of patient sampling. The ADA response will be evaluated in at least 300 ipilimumab-treated patients enrolled in the required postmarketing trial (PMR 6) comparing 3 mg/kg versus 10 mg/kg of ipilimumab monotherapy. The final report will include information on the level of ipilimumab in each patient's test sample at each sampling time point 26 Immunogenicity-Related PMCs/PMRs for Approved Biologics in the US (#2)
• Develop improved immunogenicity assays that are less sensitive to product interference that are capable of detecting human anti-human antibodies (HAHA) in the presence of belimumab at ranges that would be expected to occur in patients receiving both high and low doses • Conduct a randomized, placebo-controlled clinical trial with Benlysta (belimumab) in 5000 patients with active, autoantibody-positive systemic lupus erythematosus to evaluate Benlysta's long term safety profile including adverse events of special interest (e.g., mortality, malignancy, serious and opportunistic infections and depression/suicidality).
Krystexxa (pegloticase)
• An observational safety study enrolling 500 patients treated with Krystexxa (pegloticase) for one year duration; specifically an evaluation of the frequency and severity of infusion reactions, anaphylaxis, and immune complex-related adverse events, and identification of serious adverse events associated with Krystexxa (pegloticase) therapy. • The current anti-PEG antibody ELISA shows a very high degree of intra-and inter-assay variability possibly related to the PEG coating of the ELISA plate. This indicates either that the assay is not sufficiently optimized or that the format is unsuitable. Redevelop the anti-PEG antibody assay to address these concerns • The sensitivity of your IgE assay, as currently designed, is insufficient to detect IgE antibodies to the product. For an antigen-specific IgE assay to be useful, it should have sensitivity in the nanogram to sub-nanogram range, and there are technologies currently available that can meet this criterion. Develop a more sensitive antigen-specific IgE assay. Consider using ECL technology. • Your IgE assay was not properly validated due to a lack of positive control antibody. Develop a suitable positive control for the IgE ELISA. Cross-linking the current rabbit polyclonal to a human IgE may be an option 27 Immunogenicity-Related PMCs/PMRs for Approved Biologics in the US (#3)
Drug PMC/PMR

Nplate (romiplostim)
• To conduct an "Antibody Registry Study" that will enroll subjects who have received romiplostim and whose blood samples contain antibodies to either romiplostim or thrombopoietin. The antibody assays will be performed by Amgen in response to spontaneously submitted requests for the post-marketing blood tests. As described in the Romiplostim prescribing information, a lack or loss of response to romiplostim should prompt the healthcare provider to search for causative factors, including neutralizing antibodies to romiplostim. In these situations, healthcare providers are to submit blood samples to Amgen for detection of antibodies to romiplostim and thrombopoietin. The Antibody Registry Study will collect follow-up platelet count and other clinical data sufficient to assess the long term consequences of the detected antibodies. Patients will be followed until the detected antibodies resolve or stabilize in titer over a several month period of time. 
Conclusions
• Adverse drug affects with biologics can be quite diverse in etiology, manifestations and severity • Familial, racial and ethnic differences in genotypic/phenotypic expression may pose unique challenges in predicting efficacy and safety in select patient populations • Cytokine network is extremely complex and elaborate intracellular signaling pathway in which we have only yet begun to fully elucidate its role in disease and disease modulation Why We Care
• Most biologics will induce antibodies • Most large pharma/biotech portfolios consist of growing numbers of biologics • Avoid unintended consequences -biologics and immunogenic responses are complex • Level of sampling and monitoring dependent on potential risk • Regulators continue to raise the bar for assessment and interpretation
